

Patient Evidence Submitted for pCODR and INESSS Drug Approval Process

DATE	DRUG	REQUEST	PCODR RECOMMENDATION	INESSS RECOMMENDATION
April 2012	bendamustine (Treanda)	first line & relapsed/refractory	no	no
April 2012	bendamustine (Treanda)	first line	yes	yes
July 2014	bendamustine (Treanda) with rituxan	first line	withdrawn by manufacturer	withdrawn by manufacturer
April 2014	ofatumumab (Arzerra) with chlorambucil	first line	no	no
August 2014	obinutuzimab * (Gazyva) with chlorambucil	first line	yes	yes
August 2014	ibrutinib* (Imbruvica)	relapsed	yes	yes
April 2015	idelalisib * (Zydelig) with rituxan	relapsed	yes	yes
April 2016	ibrutinib (Imbruvica)	first line	yes	yes
July 2016	venetoclax (Venclexta)	relapsed with 17p deletion	withdrawn by manufacturer	
July 2017	venetoclax** (Venclexta)	relapsed on a B-Cell Receptor Inhibitor	yes	by Patient d'exception
October 2018	venetoclax** (Venclexta) with rituxan	relapsed	yes	yes

* with Leukemia and Lymphoma Society of Canada

** with Lymphoma Canada